Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies

被引：132
|
作者：
Shah, Nirav N. [1 ]
Maatman, Theresa [2 ]
Hari, Parameswaran [1 ]
Johnson, Bryon [1 ]
机构：
[1] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA
来源：
FRONTIERS IN ONCOLOGY | 2019年 / 9卷
关键词：
CAR-T; antigen escape; B-cell NHL; B-cell ALL; immunotherapy; ANTIGEN ESCAPE; RECEPTOR; EFFICACY; RESISTANCE; LEUKEMIA;
D O I：
10.3389/fonc.2019.00146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chimeric antigen receptor (CAR) modified T cell therapy has revolutionized the treatment of relapsed and refractory hematological malignancies. Through targeting of the CD19 antigen on B cells durable remissions have been achieved in patients with B cell non-Hodgkin lymphoma and acute lymphoblastic lymphoma. Despite impressive responses, multiple escape mechanisms to evade CAR-T cell therapy have been identified, among which the most common is loss of the target antigen. In this review we will highlight outcomes to date with CD19 CAR-T cell therapy, describe the current limitations of single targeted CAR-T therapies, review identified tumor escape mechanisms, and lastly discuss novel strategies to overcome resistance via multi-targeted CAR-T cells.
引用
收藏
页数：7
相关论文
共 50 条
  • [1] CAR-T and other adoptive cell therapies for B cell malignancies
    Lu, Peihua
    Hill, Holly A.
    Navsaria, Lucy J.
    Wang, Michael L.
    [J]. JOURNAL OF THE NATIONAL CANCER CENTER, 2021, 1 (03): : 88 - 96
  • [2] Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies
    Taha Al-Juhaishi
    Sairah Ahmed
    [J]. Current Hematologic Malignancy Reports, 2021, 16 : 32 - 39
  • [3] Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies
    Al-Juhaishi, Taha
    Ahmed, Sairah
    [J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2021, 16 (01) : 32 - 39
  • [4] CAR-T cell combination therapies in hematologic malignancies
    Zhou, Delian
    Zhu, Xiaojian
    Xiao, Yi
    [J]. EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [5] Detection, Monitoring and Cell Kinetics of Circulating CAR-T Cells in B-Cell Malignancies
    Sierro, Belen
    Beatriz Garcia-Calderon, Clara
    Sanoja-Flores, Luzalba
    Ruiz-Maldonado, Victoria
    Delgado Serrano, Javier
    Molinos-Quintana, Agueda
    Luis Reguera, Juan
    Guijarro-Albaladejo, Beatriz
    Reinoso-Segura, Marta
    Garcia-Guerrero, Estefania
    Perez-Simon, Jose A.
    Caballero, Teresa
    [J]. BLOOD, 2022, 140 : 7550 - 7551
  • [6] Targeted Therapies in Adult B-Cell Malignancies
    Rossi, Jean-Francois
    [J]. BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [7] Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches
    Gu, Tianning
    Zhu, Meng
    Huang, He
    Hu, Yongxian
    [J]. JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2022, 23 (10): : 793 - 811
  • [8] Central Nervous System Relapse after CAR-T Cell Therapy in B-Cell Malignancies
    Gu, Tianning
    Huang, Wenfa
    Wang, Lei
    Li, Yuqi
    Wang, Lixin
    Hu, Yongxian
    Huang, He
    [J]. BLOOD, 2022, 140 : 13220 - 13221
  • [9] Tisagenlecleucel: CAR-T Cell Therapy for B-cell Lymphoma
    Andres, Ulrike
    [J]. TRANSFUSIONSMEDIZIN, 2019, 9 (02)
  • [10] Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
    Rodgers, David T.
    Mazagova, Magdalena
    Hampton, Eric N.
    Cao, Yu
    Ramadoss, Nitya S.
    Hardy, Ian R.
    Schulman, Andrew
    Du, Juanjuan
    Wang, Feng
    Singer, Oded
    Ma, Jennifer
    Nunez, Vanessa
    Shen, Jiayin
    Woods, Ashley K.
    Wright, Timothy M.
    Schultz, Peter G.
    Kim, Chan Hyuk
    Young, Travis S.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (04) : E459 - E468
12345